 |
Merck OnCall® is a novel, innovative way for you to connect with Merck, providing immediate access to a LIVE Representative when you need information about Merck products or services. No special technology is required, and it’s easy and convenient to use—all you need is a telephone and Internet connection to get started. Start your Merck OnCall® session to receive instant access to a LIVE representative for VYTORIN at YOUR convenience.
Representatives are available Monday–Thursday |
VYTORIN contains 2 active ingredients: ezetimibe and simvastatin. No incremental benefit of VYTORIN on cardiovascular morbidity and mortality over and above that demonstrated for simvastatin has been established.
VYTORIN is indicated as adjunctive therapy to diet for the reduction of elevated TOTAL-C, LDL-C, Apo B, TG, and
non–HDL-C, and to increase HDL-C in patients with primary (heterozygous familial and nonfamilial) hyperlipidemia or mixed hyperlipidemia when diet alone is not enough.
non–HDL-C, and to increase HDL-C in patients with primary (heterozygous familial and nonfamilial) hyperlipidemia or mixed hyperlipidemia when diet alone is not enough.
Contraindications: hypersensitivity to any component of this medication; active liver disease; unexplained persistent elevations in hepatic transaminase levels; and women who are pregnant, nursing, or may become pregnant.
SELECTED DOSAGE AND ADMINISTRATION INFORMATION
VYTORIN is available as tablets containing 10 mg of ezetimibe combined with 10, 20, 40, or 80 mg of simvastatin
(VYTORIN 10/10, 10/20, 10/40, or 10/80 mg, respectively).
(VYTORIN 10/10, 10/20, 10/40, or 10/80 mg, respectively).
The recommended usual starting dose is 10/20 mg/day. Patients who require a larger reduction in LDL-C (greater than 55%) may be started at 10/40 mg/day. VYTORIN 10/10 mg may be considered for patients requiring less aggressive
LDL-C reduction.
LDL-C reduction.
No dosage adjustment is necessary in patients with mild or moderate renal impairment. Caution should be exercised when VYTORIN is administered to patients with severe renal insufficiency. VYTORIN should not be initiated in such patients unless the patient has already tolerated treatment with simvastatin.
Back to Top
Home | VYTORIN vs Crestor: The IN-CROSS Study | Hypothetical Patient Profiles | Selected Guidelines Information|
Head-to-Head Studies | Safety and Tolerability Profile | Other Lipid-Modifying Efficacy | Managed Care Coverage: Formulary Status |
Physician Resources | Patient Assistance Program | Educating Your Patients | Pricing | Site Map | Terms & Conditions | Privacy Policy | Copyright | Compliance Program
This site is intended only for health care professionals of the United States, its territories, and Puerto Rico.
VYTORIN and ZETIA are registered trademarks of MSP Singapore Company, LLC.
Merck OnCall® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Other brands listed are the trademarks of their respective owners and are not trademarks of MSP Singapore Company, LLC.
Copyright © 2010 Merck/Schering-Plough Pharmaceuticals, a subsidiary of Merck & Co., Inc. All rights reserved.
Home | VYTORIN vs Crestor: The IN-CROSS Study | Hypothetical Patient Profiles | Selected Guidelines Information|
Head-to-Head Studies | Safety and Tolerability Profile | Other Lipid-Modifying Efficacy | Managed Care Coverage: Formulary Status |
Physician Resources | Patient Assistance Program | Educating Your Patients | Pricing | Site Map | Terms & Conditions | Privacy Policy | Copyright | Compliance Program
This site is intended only for health care professionals of the United States, its territories, and Puerto Rico.
20852910(1)-05/10-VYT